RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
April 17, 2024
RegMed Investors (RMi) Closing Bell: start thinking of sector equities’ future direction without the geopolitical cloud overhead
April 16, 2024
RegMed Investors (RMi) Closing Bell: declining threads extend
April 11, 2024
RegMed Investors (RMi) Closing Bell: sector seeps, although with subdued selling
April 5, 2024
RegMed Investors (RMi) Closing Bell: economic circumstances drove a 5 session/weekly downside
April 4, 2024
RegMed Investors (RMi) Closing Bell: economics undermine sector’s share pricing before jobs report
April 2, 2024
RegMed Investors (RMi) Closing Bell: weakness is more of a wipe-out
April 2, 2024
RegMed Investors (RMi) - Q4/23 & FY23 Cell and Gene Therapy Earnings Scorecard Results
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors